A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 136 participants.
Also called NCT06142383
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 136 participants
- Sponsor
- Registry
-
NCT06142383
-
- Other papers using this trial's data
- The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, China, Germany, Hungary, India, Italy, Japan, Portugal, Slovakia, Spain, Taiwan
- Registry status
- Terminated
Technical summary
Registry record NCT06142383. Randomized; double masking; primary purpose treatment. Start 2023-12-12 (actual); primary completion 2024-11-01 (actual). Results posted on 2025-12-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
- Condition
- Heart Failure
- Intervention (Biological)
- Placebo
- Intervention (Biological)
- XXB750 Low dose
- Intervention (Biological)
- XXB750 Medium Dose
- Intervention (Biological)
- XXB750 High Dose
- Intervention (Drug)
- Sacubitril/valsartan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct06142383- Content hash
24603f8fa71ad905c652ca5ee7e370961736f06c7bc61b3efd1769060c9c582d